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Abstract
Background: Rates of estrogen-dependent cancers are among the highest in Western countries
and lower in the East. These variations may be attributable to differences in dietary exposures such
as higher seaweed consumption among Asian populations. The edible brown kelp, Fucus vesiculosus
(bladderwrack), as well as other brown kelp species, lower plasma cholesterol levels. Since
cholesterol is a precursor to sex hormone biosynthesis, kelp consumption may alter circulating sex
hormone levels and menstrual cycling patterns. In particular, dietary kelp may be beneficial to
women with or at high risk for estrogen-dependent diseases. To test this, bladderwrack was
administered to three pre-menopausal women with abnormal menstrual cycling patterns and/or
menstrual-related disease histories.
Case Presentation: Intake of bladderwrack was associated with significant increases in menstrual
cycle lengths, ranging from an increase of 5.5 to 14 days. In addition, hormone measurements
ascertained for one woman revealed significant anti-estrogenic and progestagenic effects following
kelp administration. Mean baseline 17β-estradiol levels were reduced from 626 ± 91 to 164 ± 30
pg/ml (P = 0.04) following 700 mg/d, which decreased further to 92.5.0 ± 3.5pg/ml (P = 0.03) with
the1.4 g/d dose. Mean baseline progesterone levels rose from 0.58 ± 0.14 to 8.4 ± 2.6 ng/ml with
the 700 mg/d dose (P = 0.1), which increased further to 16.8 ± 0.7 ng/ml with the 1.4 g/d dose (P
= 0.002).
Conclusions: These pilot data suggest that dietary bladderwrack may prolong the length of the
menstrual cycle and exert anti-estrogenic effects in pre-menopausal women. Further, these studies
also suggest that seaweed may be another important dietary component apart from soy that is
responsible for the reduced risk of estrogen-related cancers observed in Japanese populations.
However, these studies will need to be performed in well-controlled clinical trials to confirm these
preliminary findings.
Background
Epidemiological studies show that incidence rates of
estrogen-dependent diseases such as cancers of the breast,
endometrium and ovary are among the highest in West-
ern, industrialized countries, while rates are much lower
in China and Japan [1,2]. These disparities may be
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attributable, in part, to differences in dietary and environ-
mental exposures associated with affluent and modern
lifestyles that promote estrogenic stimulation and hor-
mone imbalances [3-5]. Although the mechanisms are
not fully understood, epidemiological and experimental
data suggest that exposure to estrogens, through endog-
enous production and exogenous exposures resulting in
an imbalance in the estrogen/progesterone ratio, may be
the most critical determinants in disease risk [6-8]. In
estrogen-sensitive tissues, estrogen triggers cell prolifera-
tion, and through prolonged stimulation, hyperplasia [9]
and possibly neoplasia can occur. Reproductive factors
associated with increased exposure to menstruation
resulting in persistent and sustained estrogenic stimula-
tion, such as shorter menstrual cycles, reduced parity,
early menarche, and late menopause, are known to
increase risk of endometriosis and estrogen-dependent
cancers [10,11], while post-menopausal obesity, hor-
mone replacement therapy and alcohol consumption
may be associated with increased breast cancer risk [12-
14]. Therefore, limiting exposure to estrogens and reduc-
ing the overall number of menstrual cycles in one's life-
time through dietary and lifestyle changes may be the
simplest means to reduce disease risk. In particular, the
identification of dietary compounds that have estrogen-
reducing effects holds great promise in developing chem-
opreventive strategies to abrogate risk of these diseases.
Studies show that Japanese women have longer menstrual
cycle lengths (greater than the 28 day average) and lower
circulating estrogen levels compared to Western popula-
tions [15-17], which until now has been at least partly
attributed to the increased intake of soy protein among
Asian populations [18-20]. Another less explored compo-
nent but main staple of the Japanese diet is seaweed,
which accounts for approximately 10–25% of their food
intake [21,22]. Other reported estimated daily intakes are
as high as 3–13 g/day [23]. A major source of dietary sea-
weed among Japanese populations is the edible brown
kelp, wakame (Undaria pinnatifida) and kombu (Lami-
naria japonica). These species and the Atlantic brown kelp,
bladderwrack (Fucus vesiculosus), have been shown to
exert powerful anti-hypertensive activity related to angi-
otensin-I-converting enzyme inhibition [24], to possess
antibacterial and antioxidant properties related to their
high polyphenolic content [25], and to prevent dioxin
absorption and accelerate dioxin excretion in rats [26].
Other chemopreventive properties such as antiviral activ-
ity [27,28], immunostimulatory effects [29], anti-prolifer-
ative effects on 7,12-dimethylbenz(a)-anthracene-
induced rat mammary tumors [30,31], and anti-tumor
and anti-metastatic activities in xenograft mouse models
[32], have been associated with the high level of sulfated
polysaccharides, also known as fucoidans, found in
brown seaweed.
Intake of bladderwrack, as well as other brown kelp spe-
cies, also has been shown to alter cholesterol metabolism
and to significantly lower plasma cholesterol levels
[33,34]. A possible mechanism of action involves compet-
itive inhibition by fucosterols found in kelp. Since choles-
terol is the precursor involved in steroid hormone
biosynthesis, a reduction in cholesterol bioavailability
could lower circulating plasma 17β-estradiol levels that
may lead to alterations in menstrual cycling patterns in
pre-menopausal women. Until now, no studies have been
performed in humans to determine the effects of brown
kelp on menstrual cycling patterns and sex hormone sta-
tus in pre-menopausal women, particularly in women
with or at risk for estrogen-dependent diseases. To explore
the hypothesis that kelp consumption could reduce
circulating17β-estradiol levels and attenuate menstrual
cycle irregularities, bladderwrack was administered to
three pre-menopausal women with abnormal menstrual
cycling patterns and/or menstrual-related disease
histories.
Case presentation
Three pre-menopausal women with abnormal menstrual
cycling histories volunteered for the present study. An
abnormal menstrual cycle was defined as one or more of
the following: menstrual cycles of <26 or >32 days in
length; menstrual cycles consisting of >8 menstruating
days; or anovulatory menstrual cycling. Study subject
characteristics are outlined in Table 1. Subject 1 had a his-
tory of hypermenorrhea (excessive blood loss during
menstruation), polymenorrhea (shorter than average
menstrual cycle length of 28 days), anovulatory menstrual
cycles, and was diagnosed with luteal phase deficiency
and endometriosis (through laparoscopy). Subject 2 suf-
fered from hypermenorrhea and polymenorrhea. Subject
3 suffered from hypermenorrhea and was diagnosed with
endometriosis. All three women reported a history of dys-
menorrhea (painful menses). Otherwise, all women were
in general good health and free of any chronic diseases.
All women were active and exercised approximately three
times per week. No hormones or other medications were
taken for >3 months prior to the inception of the study.
No soy protein products were consumed during the study
period.
The protocol was approved by the Committee for the Pro-
tection of Human Subjects of the University of California
at Berkeley. The nature of the study was explained, and
written informed consent was obtained from all study
subjects.
Source and dose of bladderwrack (Fucus vesiculosus)
Dried, powdered bladderwrack was obtained from Maine
Coast Sea Vegetables (Franklin, ME) and encapsulated in
350 mg capsules. Two capsules were administered dailyBMC Complementary and Alternative Medicine 2004, 4:10 http://www.biomedcentral.com/1472-6882/4/10
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for the low dose treatment (700 mg) and four capsules
were administered daily for the high dose treatment (1.4
g). Bladderwrack dosage levels were chosen to fall within
the range of reported dietary seaweed intakes (10–25%)
of the total diet reported for Japanese populations
[21,22]. This was calculated by assuming a total 500 g/d
total dietary intake and a range between 50–125 g/d (wet
weight) or 0.5–1.25 g/d (dry weight) seaweed intake. This
calculation falls below the estimated 3–13 g/d intake
reported by Teas et al. [23].
Experimental protocols
Details of the study protocol are outlined in Table 2. All
women provided self-reported menstrual cycling histories
for the three months prior to the treatment period. In
addition, 17β-estradiol and progesterone serum measure-
ments were taken for Subject 1 throughout the course of
the study as outlined in Table 2. Ovulation was monitored
through body basal temperature. Since the average length
of her cycle was 16 days prior to treatment and she was
not ovulating at the inception of the study, baseline hor-
mone levels were ascertained on a set day (menstrual cycle
day 12) for two consecutive cycles prior to the administra-
tion of 700 mg/d bladderwrack for two additional cycles.
During the treatment period, serum hormone levels were
measured on days 12 and 21 for the first cycle (which was
another anovulatory cycle) and on day 21 thereafter dur-
ing the treatment period. Subjects 2 and 3 were adminis-
tered 700 mg/d of bladderwrack beginning on day 21 of
their menstrual cycles and followed for two consecutive
cycles. Subsequently, Subjects 1 and 3 agreed to continue
the experiment for two additional cycles at which time
they received a daily dose of 1.4 g/d kelp. Menstrual
cycling logs were maintained on all subjects during the
entire course of the experiment. Subjects were monitored
at least weekly to insure compliance to the supplement
regimen.
Hormone assays
All hormone assays were performed by Quest Laborato-
ries (San Diego, CA), an outside-certified clinical
laboratory. Serum 17β-estradiol and progesterone levels
were measured in duplicate by radioimmunoassays.
Blank and control sera were run with each assay. The
Table 1: Study Subject Characteristics
Subject Age Body weight (lb) Menstrual cycle 
history
Medical conditions/
health status
Medications
1 43 142 hypermenorrhea, 
polymenorrhea, 
dysmenorrhea, luteal 
phase deficiency
endometriosis; otherwise 
healthy
none
2 42 138 hypermenorrhea, 
polymenorrhea, 
dysmenorrhea
general good health none
3 21 126 hypermenorrhea, 
dysmenorrhea
endometriosis; otherwise 
healthy
none
Table 2: Treatment protocol and timeline
Subject Pretreatment 
menstrual 
cycling history 
obtained
Pretreatment 
serum 17β-
estradiol and 
progesterone 
levels 
ascertained 
(Cycle and day)
Treatment 
period/dose
Treatment 
serum 17β-
estradiol and 
progesterone 
levels 
ascertained 
(Cycle and day)
Treatment 
period/dose
Treatment 
serum 17β-
estradiol and 
progesterone 
levels 
ascertained 
(Cycle and day)
1 Cycles 1–3 Cycle 2, day 12; 
Cycle 3, day 12
Cycle 4–5/ 700 
mg/d
Cycle 4, day 12; 
Cycle 4, day 21; 
Cycle 5, day 21
Cycle 6–7/ 1.4 g/d Cycle 6, day 21; 
Cycle 7, day 21
2 Cycles 1–3 NA Cycle 4–5/ 700 
mg/d
NA NA NA
3 Cycles 1–3 NA Cycle 4–5/ 700 
mg/d
NA Cycle 6–7/ 1.4 g/d NABMC Complementary and Alternative Medicine 2004, 4:10 http://www.biomedcentral.com/1472-6882/4/10
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coefficient of variation (a measure of laboratory error)
was consistently low (<15%) for 17β-estradiol and
progesterone.
Statistical methods
Statistical analyses were performed by unpaired t-tests (2-
sided) with a commercially available statistical software
package (Stata, College Station, Texas). All statistical tests
were considered significant for p ≤ 0.05. Results are
referred to as borderline significant for 0.05 < p ≤ 0.10.
Clinical findings
There were no adverse side effects reported and bladder-
wrack was well tolerated by all three women.
Effects of treatment on length of menstrual cycle and total 
days of menstruation
Following treatment, all women exhibited a significant
increase in menstrual cycle lengths (Figure 1). Specifically,
in Subject 1, who had a 30-year history of irregular men-
ses, the menstrual cycle length increased from an average
of 16.3 ± 0.6 days to 26.0 ± 1.4 days with the low dose
treatment (P < 0.002), which increased by approximately
5 additional days to 31.2 ± 1.1 days following administra-
tion of the higher dose (P < 0.001). In Subject 2, the aver-
age cycle length increased 5.5 days, from 23.0 ± 1.7 to
28.5 ± 0.7 days (P = 0.03). Subject 3 exhibited a 4-day
increase in menstrual cycle length from 27.3 ± 0.6 to 31.5
± 0.7 days with the 700 mg dose (P = 0.005) that increased
by approximately 6 more days to 36.0 ± 2.8 days with the
1.4 g dose (P = 0.01).
Along with increased menstrual cycle lengths, all women
reported marked reductions in blood flow and average
number of days of menstruation following bladderwrack
treatment (Figure 2). Subject 1 reported the most signifi-
cant reduction in total days of menstruation, changing
from an average 9.3 ± 0.6 to 6.3 ± 1.8 days (P = 0.06) with
the low dose and to 4.5 ± 0.7 average days with the high
dose (P < 0.003). Subject 2, who only took the low dose,
also experienced a marked reduction in number of days of
menstruation, from 8.0 ± 1.0 to 5.3 ± 2.5 days (P = 0.06).
Subject 3 exhibited a decrease in total menstruating days
averaging from 6.3 ± 1.5 to 5.8 ± 0.4 days (P = 0.65) with
the low dose, and to 3.5 ± 0.7 days (P = 0.10) with the 1.4
g/d dose. Subjects 1 and 3, who both suffered from
endometriosis, reported substantial alleviation from pain
during menstruation and throughout the menstrual cycle
following bladderwrack treatment.
Subject 1 also reported an ovulatory cycle following 2
months on the 700 mg/d kelp intervention, and contin-
ued to have ovulatory cycles while on the 1.4 g/d dose.
Average menstrual cycle length in days for Subjects 1–3 at baseline (black bars) and following bladderwrack administration of  700 mg/d (diagonal striped bars) and 1.4 g/d (white bars) Figure 1
Average menstrual cycle length in days for Subjects 1–3 at baseline (black bars) and following bladderwrack administration of 
700 mg/d (diagonal striped bars) and 1.4 g/d (white bars). Black bars indicate the averages of 3 menstrual cycles; diagonal 
striped and white bars indicate the averages of 2 menstrual cycles; and whiskers indicate standard deviations. * P value <0.05.
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Effects of treatment on serum estradiol and progesterone 
levels
A significant anti-estrogenic and progestagenic dose
response was observed in plasma estradiol and
progesterone levels in Subject 1 (Table 3). Specifically, the
mean baseline 17β-estradiol levels were reduced from 626
± 91 to 164 ± 30 pg/ml (P = 0.04) with the low dose (700
mg/d), which decreased further to 92.5 ± 3.5 pg/ml (P =
0.03) with the higher dose (1.4 g/d). Furthermore, mean
baseline progesterone level rose from 0.58 ± 0.14 to 8.4 ±
2.6 ng/ml with the lower 700 mg/d dose (P = 0.1), which
increased further to 16.8 ± 0.7 ng/ml with the 1.4 g/d dose
(P = 0.002).
Discussion of clinical findings
The results of this preliminary pilot study suggest that
bladderwrack consumption can effectively increase the
length of the menstrual cycle and reduce the total number
of days of menstruation in pre-menopausal women.
These effects were most marked in the two women that
had shorter than average cycles (16 and 23 days) versus
the normal range of 26 to 32 days seen in women in West-
ern populations. Menstrual cycles were further lengthened
with increasing dose, which may suggest a linear dose-
response effect. However, since there was not a sufficient
washout period between the 700 and 1400 mg/d doses,
an effect of length of time of dosing rather than a dose
response effect cannot be ruled out. Nonetheless, these
marked increases in menstrual cycle length may have ben-
eficial health effects in lowering risk of estrogen-depend-
ent diseases such as endometriosis and ovarian,
endometrial, and breast cancers as reported in a number
of studies [16,35-38]. Menstrual characteristics are
surrogate markers that may reflect a woman's overall
exposure to and production of endogenous hormones.
Shorter menstrual cycle lengths and prolonged menstrua-
tion confer longer follicular and luteal phases where estro-
gen and progesterone levels and endometrial and breast
cell proliferation rates are at their highest. A nearly four-
fold increase in mitotic activity in the breast lobules
occurs during the luteal phase of the menstrual cycle [39],
while the highest proliferation rates (nearly 100-fold) in
the endometrium occur during the follicular phase [40].
Therefore, fewer menstrual cycles over a woman's lifetime
would decrease the amount of time during which the
breast and endometrial epithelia would be exposed to
high levels of proliferation, which may decrease overall
disease risk.
Average number of days of menstruation per cycle for Subjects 1–3 at baseline (black bars) and following bladderwrack admin- istration of 700 mg/d (diagonal striped bars) and 1.4 g/d (white bars) Figure 2
Average number of days of menstruation per cycle for Subjects 1–3 at baseline (black bars) and following bladderwrack admin-
istration of 700 mg/d (diagonal striped bars) and 1.4 g/d (white bars). Each bar indicates averages from two menstrual cycles; 
whiskers indicate standard deviations. * P value <0.05.
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Bladderwrack consumption also led to a marked reduc-
tion in circulating 17β-estradiol levels and an increase in
progesterone levels in a subject who exhibited high serum
estrogen levels and progesterone deficiency prior to the
intervention. While estrogen's proliferative effects on
mammary gland development and endometrial and
breast tumorigenesis are well documented, progesterone's
role in these processes is not as well defined. Studies show
that progesterone deficiency is associated with increased
endometrial cancer incidence [41], and that progesterone
inhibits estrogen-induced luminal epithelial proliferation
in the uterus [42]. However, progesterone has been shown
to both stimulate and inhibit the growth of experimental
mammary tumors [43], and the use of synthetic pro-
gestins in hormone replacement therapy has been associ-
ated with an increased risk of breast cancer [43].
Experimental rat models have elucidated progesterone's
vital role in pregnancy-induced morphological changes in
the breast, which confer protection against breast cancer
[44]. Further, epidemiological studies suggest that it is not
pregnancy alone but early first parity and increasing
number of pregnancies that are associated with reduced
breast cancer risk [45,46]. These studies suggest that the
effects of progesterone in breast cancer risk may be
dependent on timing and the type and level of progester-
one/progestin exposure. Thus, the anti-estrogenic/pro-
gestagenic activity of kelp observed in this study warrants
further investigation in its role in breast cancer and other
hormone-dependent diseases.
Study limitations
Due to the small number of subjects and the lack of a con-
trol group, this study will need to be repeated in a larger,
randomized population of women with placebo controls.
Other weaknesses of the present study are the lack of data
on luteinizing hormone and follicular stimulating hor-
mone levels which would provide pertinent information
regarding the effects of dietary bladderwrack on ovulation
and the luteal and follicular phases of the menstrual cycle.
The potential beneficial impact that dietary bladderwrack
may have on abrogating symptoms of endometriosis war-
rants a closer look at a larger population of women suffer-
ing from this disease. However, studies should also be
performed in women with normal menstrual cycles who
have sex hormone levels within clinically normal ranges
to determine the impact of dietary kelp on menstrual
cycling patterns and hormone levels in the general
population.
Conclusions
The observed responses to bladderwrack consumption in
this study suggest that dietary modification may lead to
significant changes in the regulation of the menstrual
cycle by increasing the length of the cycle, stimulating
ovulation, and lowering the estrogen/progesterone ratio
in pre-menopausal women. Such changes may be benefi-
cial particularly with regard to women at high risk of
estrogen-dependent diseases or who are experiencing fer-
tility problems. Results from these preliminary experi-
ments also suggest that bladderwrack administration may
alleviate hypermenorrhea and dysmenorrhea, which may
provide some relief in the treatment of endometriosis.
Although these reported effects are generally in a benefi-
cial direction, their clinical significance is yet to be deter-
mined in a well-controlled study.
Future Directions
The critical role of hormones in breast, endometrial, and
ovarian cancers in women and prostate cancer in men has
long been recognized. Given the vast rise of these cancers
in the U.S. and our limited success with prevention and
treatment, there is clearly a need for the identification of
novel, non-cytotoxic chemopreventive agents. Future
investigations should clarify the role of bladderwrack and
other seaweed species on estrogen and progesterone
metabolism, to evaluate its potential binding affinity to
estrogen and progesterone receptors, and to determine its
effects on proliferation in hormone-sensitive tissues.
These investigations should also be expanded to include
effects of bladderwrack on other sex hormones including
the androgens and gonadotropins. In this regard, animal
and in vitro studies are currently underway in our labora-
tory to elucidate the potential mechanisms and clinical
relevance of bladderwrack bioactivity, and to identify and
isolate the active components involved.
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Table 3: Average circulating plasma 17β-estradiol and progesterone levels prior to and during kelp intervention for Subject 1
Pre-treatment 
baseline levels
700 mg/d dose P-value 1.4 g/d dose P-value
17β-estradiol (pg/ml) 626 ± 91 164 ± 30 0.04 92.5 ± 3.5 0.03
Progesterone (ng/ml) 0.58 ± 0.14 8.4 ± 2.6 0.10 16.8 ± 0.7 0.002
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